Tachyon Therapeutics
Tachyon is an oncology-focused biotechnology company accelerating development of first-in-class therapeutics that target epigenetic drivers of cancer. The organization uses an internal core development team plus a distributed external network, and emphasizes discovery using single-cell genomic analysis, preclinical evaluation in cell lines, patient-derived organoids and xenograft models, biomarker identification, and early clinical development (Phase 1) of orally available small-molecule inhibitors against the KDM4 family.
Industries
Nr. of Employees
small (1-50)
Tachyon Therapeutics
Products
TACH101
A first-in-class, orally available small-molecule pan-inhibitor of the KDM4 histone demethylase family developed for treatment of advanced or metastatic cancers; progressed to first-in-human Phase 1 clinical testing.
TACH204
A therapeutic antibody developed to inhibit LEFTY1, a member of the TGF-beta superfamily involved in cancer stem cell renewal and tumorigenesis, particularly in breast cancer.
TACH101
A first-in-class, orally available small-molecule pan-inhibitor of the KDM4 histone demethylase family developed for treatment of advanced or metastatic cancers; progressed to first-in-human Phase 1 clinical testing.
TACH204
A therapeutic antibody developed to inhibit LEFTY1, a member of the TGF-beta superfamily involved in cancer stem cell renewal and tumorigenesis, particularly in breast cancer.
Expertise Areas
- Epigenetic drug discovery
- Oncology drug development
- Single-cell genomics
- Preclinical model development (organoids, xenografts)
Key Technologies
- Single-cell genomic analysis
- Patient-derived organoid (3D) models
- In vivo xenograft models
- Small-molecule medicinal chemistry
News & Updates
Peer-reviewed article describing TACH101 as a pan-KDM4 inhibitor and its preclinical characterization.
Conference abstract presented in J Clin Oncol discussing TACH101 for gastrointestinal cancers.
Abstract describing identification of pharmacodynamic and sensitivity biomarkers for the KDM4 inhibitor.
Conference abstract addressing application of the KDM4 inhibitor in triple-negative breast cancer models.
Conference abstract reporting pharmacologic characterization of the KDM4 inhibitor.
Peer-reviewed article describing TACH101 as a pan-KDM4 inhibitor and its preclinical characterization.
Conference abstract presented in J Clin Oncol discussing TACH101 for gastrointestinal cancers.
Abstract describing identification of pharmacodynamic and sensitivity biomarkers for the KDM4 inhibitor.
Conference abstract addressing application of the KDM4 inhibitor in triple-negative breast cancer models.
Conference abstract reporting pharmacologic characterization of the KDM4 inhibitor.